Point72 Asset Management L.P. Acquires Shares of 872,959 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Point72 Asset Management L.P. acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 4th quarter, HoldingsChannel reports. The firm acquired 872,959 shares of the company’s stock, valued at approximately $16,447,000.

Several other institutional investors also recently modified their holdings of the stock. US Bancorp DE increased its holdings in shares of Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after buying an additional 842 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Nurix Therapeutics during the fourth quarter worth $87,000. Summit Investment Advisors Inc. increased its holdings in shares of Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after buying an additional 877 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Nurix Therapeutics during the fourth quarter worth $164,000. Finally, Nomura Holdings Inc. acquired a new position in shares of Nurix Therapeutics during the fourth quarter worth $198,000.

Insider Buying and Selling at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $488,660.76. This trade represents a 14.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the transaction, the insider now directly owns 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NRIX. Wells Fargo & Company lowered their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. Royal Bank of Canada upped their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Stephens reiterated an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Finally, Leerink Partners assumed coverage on Nurix Therapeutics in a report on Monday, March 17th. They issued a “market perform” rating and a $16.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $30.44.

Nurix Therapeutics Trading Up 1.1%

Shares of NRIX opened at $9.56 on Friday. The stock has a market capitalization of $728.82 million, a P/E ratio of -3.31 and a beta of 2.23. The firm’s fifty day simple moving average is $11.07 and its two-hundred day simple moving average is $16.86. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same quarter in the prior year, the firm posted ($0.76) earnings per share. As a group, research analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.